Lisata Therapeutics Reported Earnings

Lisata Therapeutics (LSTA) reported a loss of $0.32 per share on revenue of $0.00 million for the second quarter ended June 2026. . Revenue fell 100.00% compared to the same quarter a year ago.

Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.